Beijing Tiantan Biological Products Co., Ltd. (SHA: 600161)
China
· Delayed Price · Currency is CNY 22.62
-0.18 (-0.79%)
Nov 13, 2024, 3:00 PM CST
Beijing Tiantan Biological Products Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 1,274 | 1,110 | 880.92 | 760.01 | 639.01 | 611.09 | Upgrade
|
| Depreciation & Amortization | 265.22 | 265.22 | 179.75 | 157.15 | 132.75 | 128.21 | Upgrade
|
| Other Amortization | 23.62 | 23.62 | 12.39 | 8.38 | 9.45 | 6.63 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.05 | 0.05 | -15.63 | -0.51 | 0.12 | 0.1 | Upgrade
|
| Asset Writedown & Restructuring Costs | 1.21 | 1.21 | 2.1 | 15.09 | 0.57 | 0.88 | Upgrade
|
| Loss (Gain) From Sale of Investments | -37.21 | -37.21 | -28.13 | -12 | -1.15 | -0.21 | Upgrade
|
| Provision & Write-off of Bad Debts | -0.65 | -0.65 | 1.26 | -0.14 | -0.55 | 0.27 | Upgrade
|
| Other Operating Activities | -800.73 | 405.98 | 327.41 | 314.14 | 307.97 | 286.08 | Upgrade
|
| Change in Accounts Receivable | 1,029 | 1,029 | -221.05 | -351.21 | -82.48 | -217.09 | Upgrade
|
| Change in Inventory | -514.44 | -514.44 | -181.5 | 30.96 | -222.66 | -241.31 | Upgrade
|
| Change in Accounts Payable | 98.57 | 98.57 | 167.42 | 66.15 | -73.05 | 97.71 | Upgrade
|
| Operating Cash Flow | 1,351 | 2,394 | 1,126 | 980.35 | 702.11 | 642.47 | Upgrade
|
| Operating Cash Flow Growth | -46.27% | 112.57% | 14.86% | 39.63% | 9.28% | -5.23% | Upgrade
|
| Capital Expenditures | -1,081 | -1,078 | -1,354 | -1,132 | -608.91 | -526.23 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.34 | 0.31 | 0.71 | 8.51 | 0.61 | 16.87 | Upgrade
|
| Cash Acquisitions | -5.16 | -1.58 | -36.36 | -29.33 | - | -30.35 | Upgrade
|
| Investment in Securities | 25.33 | - | - | -1,030 | -11.01 | -25 | Upgrade
|
| Other Investing Activities | 489.5 | -168.1 | -481.24 | -2.44 | -1.16 | -1.11 | Upgrade
|
| Investing Cash Flow | -571.35 | -1,247 | -1,871 | -2,185 | -620.47 | -565.82 | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | 400 | 169.21 | Upgrade
|
| Long-Term Debt Repaid | - | -385.85 | -132.8 | -366.17 | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -204.2 | -385.85 | -132.8 | -366.17 | 400 | 169.21 | Upgrade
|
| Issuance of Common Stock | - | - | - | 3,332 | - | - | Upgrade
|
| Common Dividends Paid | -248.41 | -94.02 | -157.21 | -163.84 | -92.88 | -60.36 | Upgrade
|
| Other Financing Activities | -134.85 | -28.21 | -88.19 | -27.6 | -52.95 | -21.97 | Upgrade
|
| Financing Cash Flow | -587.46 | -508.08 | -378.2 | 2,774 | 254.17 | 86.87 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.07 | -0 | -0.05 | -0.01 | -0.22 | -0.55 | Upgrade
|
| Net Cash Flow | 192.32 | 638.58 | -1,123 | 1,570 | 335.59 | 162.98 | Upgrade
|
| Free Cash Flow | 269.83 | 1,316 | -228.02 | -151.35 | 93.2 | 116.24 | Upgrade
|
| Free Cash Flow Growth | -78.48% | - | - | - | -19.82% | -69.73% | Upgrade
|
| Free Cash Flow Margin | 5.16% | 25.40% | -5.35% | -3.68% | 2.71% | 3.54% | Upgrade
|
| Free Cash Flow Per Share | 0.14 | 0.66 | -0.11 | -0.08 | 0.05 | 0.06 | Upgrade
|
| Cash Income Tax Paid | 622.43 | 582.34 | 412.48 | 386.75 | 363.05 | 371.7 | Upgrade
|
| Levered Free Cash Flow | -443.73 | 1,047 | -348.46 | -470.29 | -127.06 | -33.09 | Upgrade
|
| Unlevered Free Cash Flow | -441.59 | 1,049 | -346.96 | -468.36 | -125.2 | -33.09 | Upgrade
|
| Change in Net Working Capital | 893.5 | -771.71 | -6.78 | 235.97 | 314.03 | 280.08 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.